Gilead shares climb after its L.A.-area Kite unit gets FDA approval for lymphoma therapy

Gilead Sciences Inc.’s stock rose Thursday morning after the biotech company’s Kite Pharma unit gained federal approval for its flagship cell-treatment therapy for adults with advanced lymphoma.

The Food and Drug Administration’s approval Wednesday of Kite’s treatment represented a rapid payoff...

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

Gilead Sciences Inc [+]    Kite Pharma [+]    Wednesday of Kite [+]   

More #news: